Age Related Macular Degeneration Clinical Trial
Official title:
Eye Movement Rehabilitation in Low Vision Patients
Approximately 217 million people worldwide currently suffer from low vision, which impacts a broad range of activities of daily living and is associated with depression and increased mortality. Over half of the patients presenting for low vision services have eye disease that affects the fovea and surrounding macula and leads to central vision loss (CVL). People with CVL are forced to use eccentric vision as a substitute for their impaired fovea, however eye movement control and visual function is impaired with eccentric vision. Recent evidence and preliminary results from the investigators show that rehabilitation methods can help improve oculomotor control and this can lead to improved functional outcomes. The investigators have developed new feedback-based training methods that aim to improve eccentric vision use by patients with CVL. In a series of studies, the investigators examine rehabilitation of fixation control, smooth pursuit eye movements that track moving objects and saccadic eye movements that abruptly change the point of regard. The investigators examine how visual feedback, scotoma awareness methods and hand-eye coordination can improve eccentric vision use. Improvements in oculomotor control are quantified with eye tracking methods and associated changes in visual function are quantified with acuity, contrast sensitivity and reading performance. The proposed research therefore develops and translates state-of-the-art methods in basic science to clinical applications. Accomplishing the proposed aims will provide new and improved methods for rehabilitation strategies for visual impairment. The ultimate goal of this proposal is to maximize the residual visual function of people with low vision and to help them to live independently, thereby improving quality of life and minimizing the economic and social burden of visual impairment.
Status | Recruiting |
Enrollment | 106 |
Est. completion date | January 31, 2024 |
Est. primary completion date | May 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 14 Years to 99 Years |
Eligibility | Inclusion Criteria: - over 14 year of age - logMAR Acuity 0.5-1.0 - Bi-lateral foveal scotomas < 7 °radius - Mini Mental State questionnaire = 29 - no history of concurrent peripheral vision loss Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
United States | NECO Center for Eye Care | Boston | Massachusetts |
United States | Lighthouse Guild | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Northeastern University | Lighthouse Guild, National Eye Institute (NEI), New England College of Optometry |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Visual Acuity | The smallest band-pass filtered letter that can be identified at 100% contrast | Before, immediately after and 2 weeks after behavioral intervention | |
Primary | Change in Contrast Sensitivity | The lowest contrast band-pass filtered letter that can be identified as a function of spatial frequency | Before, immediately after and 2 weeks after behavioral intervention | |
Primary | Change in Fixation control | Bivariate Contour Ellipse Area of Fixation (degrees of visual angle) | Before, immediately after and 2 weeks after behavioral intervention | |
Primary | Change in Saccadic Eye Movement Latency | Latency (msec) after stimulus displacement before onset of saccadic eye movement | Before, immediately after and 2 weeks after behavioral intervention | |
Primary | Change in Saccadic Eye Movement Amplitude | Amplitude (degrees per sec) of eye movements between fixation targets | Before, immediately after and 2 weeks after behavioral intervention | |
Primary | Change in Smooth Pursuit Eye Movement Latency | Latency (msec) after stimulus movement before onset of pursuit eye movement | Before, immediately after and 2 weeks after behavioral intervention | |
Primary | Change in Smooth Pursuit Eye Movement Gain | Gain (ratio of eye movement speed divided by stimulus speed) during stimulus movement | Before, immediately after and 2 weeks after behavioral intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03963817 -
Snapshot Camera for AMD
|
||
Completed |
NCT04779398 -
Association of MPOD Values With Blue Light.
|
||
Terminated |
NCT03275753 -
Visual Function Tests in Age-related Macular Degeneration
|
||
Recruiting |
NCT03609307 -
Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial
|
Phase 2/Phase 3 | |
Completed |
NCT02909985 -
Visual Activity Evoked by Infrared in Humans After Dark Adaptation
|
N/A | |
Completed |
NCT02556723 -
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
|
N/A | |
Active, not recruiting |
NCT01943396 -
Treatment of AMD With Rheohemapheresis /RHF/
|
Phase 4 | |
Completed |
NCT00963339 -
Age-Related Macular Degeneration (AMD) - Usability Study
|
N/A | |
Completed |
NCT00376701 -
Combination Therapy for Age-Related Macular Degeneration.
|
Phase 2 | |
Terminated |
NCT00347165 -
Intravitreal Bevacizumab for Age-Related Macular Degeneration
|
Phase 2 | |
Completed |
NCT00800995 -
Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD)
|
Phase 3 | |
Completed |
NCT04689789 -
OCTA and Retinal Angiomatous Proliferation
|
||
Completed |
NCT02567604 -
Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
|
||
Completed |
NCT02173496 -
Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
|
||
Recruiting |
NCT01991730 -
Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients
|
N/A | |
Active, not recruiting |
NCT01657669 -
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
|
Phase 4 | |
Completed |
NCT00776763 -
Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab
|
Phase 2 | |
Completed |
NCT00791570 -
Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy
|
Phase 1 | |
Completed |
NCT00413829 -
Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB)
|
Phase 2 | |
Completed |
NCT00358345 -
PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization
|
Phase 4 |